Payers have been rolling out disease management programs as a way to both control costs and improve outcomes for patients with chronic diseases, such as chronic obstructive pulmonary disease, asthma, diabetes, and others. But what happens to health outcomes when components of care considered COPD disease management in the United States are considered part of usual care elsewhere in the world?